Merck & Co. last week began its...

...U.S. commercial launch of Ontruzant, a biosimilar to Roche's Genentech division's Herceptin. Ontruzant's list price is set at $1,325 for a single 150 mg dose, which is about 15% cheaper than Genentech's product. For the treatment of HR+ and HER2+ metastatic breast cancer, Herceptin is covered in the pharmacy benefit for 44% of covered lives, the medical benefit for 23% of covered lives, and both the medical and pharmacy benefit for 25% of covered lives. In the pharmacy benefit, Herceptin holds preferred status for 12% of covered lives, growing to 19% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 4/15/20